Clinofibrate

SKU: orb1300759

Description

Clinofibrate (Lipoclin) is a lipid-lowering agent that inhibits HMG-CoA reductase (IC50 = 0.47 mM). It is used in research to study cholesterol and triglyceride metabolism, with applications in both in vitro enzymatic assays and in vivo models of hyperlipidemia.

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 30299-08-2
• MW: 468.58
• Purity: >99.99% (May vary between batches)
• Formula: C₂₈H₃₆O₆
• SMILES: O(C(C(O)=O)(CC)C)C1=CC=C(C2(CCCCC2)C3=CC=C(OC(C(O)=O)(CC)C)C=C3)C=C1
• Target: Autophagy,HMG-CoA Reductase
• Solubility: DMSO:87 mg/mL (185.67 mM);Ethanol:87 mg/mL (185.67 mM)

Bioactivity

• Target IC50:
  HMG-CoA reductase:0.47 mM
• In Vivo:
  Clinofibrate, with an IC50 of 40 μM, acts on the activity of human liver 3α-hydroxysteroid dehydrogenase.
• In Vitro:
  In the treatment of arteriosclerosis in rats, Clinofibrate significantly reduces high plasma cholesterol levels. When used in CAPD patients, it effectively decreases very low-density lipoprotein levels. Typically, Clinofibrate (600 mg/daily) reduces serum triglycerides by 36% and very low-density lipoprotein triglycerides by 48%. Additionally, it ameliorates abnormalities in low-density and high-density lipoprotein compositions, markedly increasing the content of high-density lipoprotein cholesterol.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

S8527, S-8527, S 8527, HMGCoA Reductase, HMG-CoA Reductase (HMGCR), HMGCoAReductase, HMGCR, Inhibitor, Lipoclin, inhibit, Clinofibrate, Autophagy

Compound Identifiers

PubChem CID

2787